<DOC>
	<DOC>NCT01661257</DOC>
	<brief_summary>This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab) therapy.</brief_summary>
	<brief_title>Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy</brief_title>
	<detailed_description>The immunoregulatory effects of TIM-3 on patients with Crohn's disease according to the treatment have not yet been investigated.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>•Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings •patients who has proven to have infliximab antibody</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Crohn's disease</keyword>
	<keyword>Infliximab</keyword>
	<keyword>T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3)</keyword>
</DOC>